Merit Medical Systems Inc

Merit Medical Systems Inc(MMSI)股票分析

$89.960

+0.765 (+0.85%)收盘时

Loading chart…
最高
90.740
开盘
88.850
成交量加权均价
89.85
成交量
580.99K
市值
4.85B
最低
88.850
成交额
52.20M
企业价值/息税折旧摊销前利润(TTM)
14.73

Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.

AI 分析 of Merit Medical Systems Inc (MMSI)

买入

Merit Medical Systems Inc (MMSI) is a good buy right now due to its strong recent performance, including a 10% year-over-year revenue growth in Q2 2026, and a current price of $89.2, which is below the average analyst price target of $97. Additionally, the company has a forward P/E ratio of 18.94, indicating potential for growth relative to its earnings. However, a risk to consider is the significant insider selling, which has increased by 1341.20% over the last month, suggesting potential concerns from insiders about the stock's future performance.

分析师评级(9)

上行空间 +16.31%
买入
8 买入
1 持有
0 卖出
当前: 89.96
最低
90.00
平均
104.63
最高
122.00

BofA

2026-08-12

目标价

$97

中性

Canaccord

2026-08-03

目标价

$94

买入

BTIG

2026-07-31

目标价

$105

买入

Raymond James

2026-07-31

目标价

$100

跑赢大盘

Barrington

2026-07-31

目标价

$114

跑赢大盘

估值指标

Merit Medical Systems Inc(MMSI)当前预期市盈率为 18.94,5 年平均预期市盈率为 24.12。

预期市盈率

低估
5 年均值 P/E
24.12
当前P/E
18.94
高估
27.48
低估
20.76

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
16.85
当前EV/EBITDA
14.73
高估
19.07
低估
14.64

预期市销率

合理
5 年均值 P/S
3.27
当前P/S
3.07
高估
3.75
低估
2.79

Alphio AI 对 MMSI 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%MMSI

$115.59

情景价格

基

基准

基准 · 50%MMSI

$110.74

情景价格

悲

悲观

悲观 · 25%MMSI

$87.37

情景价格

持有 MMSI 的大户

M

Maverick Capital, Ltd.

+ 持有MMSI

+4.02%

3个月收益率

J

J. Goldman & Co., L.P.

+ 持有MMSI

+2.90%

3个月收益率

W

Westwood Management Corp.

+ 持有MMSI

+0.25%

3个月收益率

事件时间线

2026-07-30 (ET)

20:30:00

Amazon Earnings Beat Expectations, Stock Rises Nearly 10%

16:30:00

Merit Raises FY26 Revenue Outlook to $1.631B-$1.643B

2026-04-30 (ET)

16:21:00

Company Narrows FY26 Revenue View to $1.612B-$1.634B

16:21:00

Merit Q1 Revenue Exceeds Expectations at $381.9M

资讯

MMSI 常见问题 —— 由 Alphio AI 解答

Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Merit Medical Systems Inc (MMSI) is a good buy right now due to its strong recent performance, including a 10% year-over-year revenue growth in Q2 2026, and a current price of $89.2, which is below the average analyst price target of $97. Additionally, the company has a forward P/E ratio of 18.94, indicating potential for growth relative to its earnings. However, a risk to consider is the significant insider selling, which has increased by 1341.20% over the last month, suggesting potential concerns from insiders about the stock's future performance.

9 analysts cover MMSI: 8 rate it Buy, 1 Hold and 0 Sell. The average price target is 104.63.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易